Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today ...

ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic ...

A Ukrainian drone boat was found acting as a carrier for fiber-optic drones, Russian reports say. It's the first time these unjammable quadcopters have been reported in Ukraine's naval warfare. Both ...

Not only could insurance be affected, but drivers could also face fines of up to £1,000 or even prosecution if they fail to ...

ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and ...

A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

Stockton's recruitment and hiring practices came under scrutiny at a recent Council Audit Committee meeting, where councilmembers questioned why employees in a newly created city division were hired ...

Deep learning tech using OCT scans may improve the diagnostic accuracy of optic nerve head atrophy. Three-dimensional (3D) deep learning modeling of optical coherence tomography (OCT) scans of ...

A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...

New research links two widely used diabetes drugs, semaglutide or tirzepatide, to a rare but potentially vision-threatening eye condition, raising questions about drug-specific risks and the need for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 2 ACUITY trial met its primary safety endpoint ...